Impact of biological agents on postsurgical complications in inflammatory bowel disease: a multicentre study of geteccu

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author García, María José
• dc.contributor.author González-Vivó, María
• dc.contributor.author Gisbert, Javier P.
• dc.contributor.author The Young Group of Geteccu
• dc.date.accessioned 2022-06-21T06:49:03Z
• dc.date.available 2022-06-21T06:49:03Z
• dc.date.issued 2021
• dc.description.abstract Background: The impact of biologics on the risk of postoperative complications (PC) in inflammatory bowel disease (IBD) is still an ongoing debate. This lack of evidence is more relevant for ustekinumab and vedolizumab. Aims: To evaluate the impact of biologics on the risk of PC. Methods: A retrospective study was performed in 37 centres. Patients treated with biologics within 12 weeks before surgery were considered "exposed". The impact of the exposure on the risk of 30-day PC and the risk of infections was assessed by logistic regression and propensity score-matched analysis. Results: A total of 1535 surgeries were performed on 1370 patients. Of them, 711 surgeries were conducted in the exposed cohort (584 anti-TNF, 58 vedolizumab and 69 ustekinumab). In the multivariate analysis, male gender (OR: 1.5; 95% CI: 1.2-2.0), urgent surgery (OR: 1.6; 95% CI: 1.2-2.2), laparotomy approach (OR: 1.5; 95% CI: 1.1-1.9) and severe anaemia (OR: 1.8; 95% CI: 1.3-2.6) had higher risk of PC, while academic hospitals had significantly lower risk. Exposure to biologics (either anti-TNF, vedolizumab or ustekinumab) did not increase the risk of PC (OR: 1.2; 95% CI: 0.97-1.58), although it could be a risk factor for postoperative infections (OR 1.5; 95% CI: 1.03-2.27). Conclusions: Preoperative administration of biologics does not seem to be a risk factor for overall PC, although it may be so for postoperative infections.
• dc.format.mimetype application/pdf
• dc.identifier.citation García MJ, Rivero M, Miranda-Bautista J, Bastón-Rey I, Mesonero F, Leo-Carnerero E, et al. Impact of biological agents on postsurgical complications in inflammatory bowel disease: a multicentre study of geteccu. J Clin Med. 2021 Sep 26; 10(19): 4402. DOI: 10.3390/jcm10194402
• dc.identifier.doi http://dx.doi.org/10.3390/jcm10194402
• dc.identifier.issn 2077-0383
• dc.identifier.uri http://hdl.handle.net/10230/53549
• dc.language.iso eng
• dc.publisher MDPI
• dc.rights Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/ 4.0/
• dc.subject.keyword Crohn’s disease
• dc.subject.keyword Anti-TNF
• dc.subject.keyword Inflammatory bowel disease
• dc.subject.keyword Postoperative complications
• dc.subject.keyword Preoperative therapy
• dc.subject.keyword Surgery
• dc.subject.keyword Ulcerative colitis
• dc.subject.keyword Ustekinumab
• dc.subject.keyword Vedolizumab
• dc.title Impact of biological agents on postsurgical complications in inflammatory bowel disease: a multicentre study of geteccu
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion